An American Journal of Managed Care Forum: Managed Care Perspectives on the Challenges and Opportunities to Improve Patient Outcomes in the Management of Overactive Bladder

Program Description

Overactive bladder (OAB) is a chronic disease that affects the quality of life of about 16.5% of the US population due to urinary incontinence or frequent need to urinate. Managed care professionals and pharmacists have important roles in providing education about OAB and adherence to treatment, as well as ensuring patient access to therapies. Current guidelines recommend combination treatment with behavioral therapy along with a pharmacologic agent such as the antimuscarinic and beta-3 adrenergic agonist classes, which work to control motility of contents in the bladder. Managed care professionals must weigh the risks and benefits for each agent to individualize treatments and assign costs based on dosages, dose adjustments, comorbidities, and adverse effect profiles while considering impact on the patient’s quality of life. The panelists will discuss therapy options managed care professionals need to be aware of to remove access barriers and improve health outcomes in patients with OAB. A patient perspective interview ingrained throughout the program will highlight the challenges a patient with OAB experiences and the role of managed care professionals in supporting patient management. 

Target audience: Managed care pharmacists

Type of activity: Application
Release date: January 31, 2023
Expiration date: January 31, 2024

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the prevalence and treatment challenges of overactive bladder (OAB) and its impact on quality of life
• Examine the guideline recommendations and clinical data for the treatment of OAB to make clinical recommendations tailored to patient need
• Establish the managed care strategies for overcoming treatment challenges and promoting individualized care for patients with OAB

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-434-H01-P. The activity is available for CE credit through January 31, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sunny Linnebur, PharmD, BCGP, BCPS, FCCP, FASCP, has the following financial relationships with commercial interests to disclose:
Consultant: CVS Caremark Pharmacy and Therapeutics Committee member, Colorado Access Pharmacy and Therapeutics Committee member, Merck Manual textbook author

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Bilal Chughtai, MD, and Nazia Rashid, PharmD, MS

Medical Writer

Spencer K. Yingling, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms